Replies to post #237594 on Biotech Values

[HDGabor]

D-

Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved preclinical pharmacology. Wave expects to initiate dosing in a Phase 1b/2a clinical trial for WVE-003 in 2021.

Best,
G

[DewDiligence]

WVE +20% on GSK collaboration—$170M up-front cash (including $50M equity investment):

https://finance.yahoo.com/news/wave-life-sciences-gsk-announce-123000873.html